Lead Program

all catalysts(0)

nothing on the calendar yet

News(10)

• Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
  In exchange for a $575 million payment up front, Abogen Biosciences will furnish Novartis with access to its RNA technology, including an option to license its lead program ABO-2203.
  biopharma_dive · 11h ago
• Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
  Roche has penned a backloaded $2 billion deal with hematology biotech Atavistik Bio to develop allosteric small molecules for cardiometabolic diseases.
  fiercebiotech · 8d ago
• Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
  Novo’s attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug after less than two…
  fiercebiotech · 17d ago
• NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand
  After tinkering with the biology of the broadly appealing anti-inflammatory NLRP3 pathway, NodThera is now plotting its pivotal trial plans for 2027. The decade-old biotech said Wednesday it is reb…
  endpoints · 23d ago
• A new immuno-oncology play raises $225M for a next-generation drug
  Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.
  biopharma_dive · 23d ago
• Alumis' TYK2 drug fails in lupus trial; CEO sees 'clear path forward'
  Alumis' lead drug program suffered a clinical setback Tuesday as the San Francisco biotech reported its TYK2 pill failed a mid-stage lupus study. The results put a damper on what has ...
  endpoints · 1mo ago
• Lilly adds to immune drug pipeline with $2.9B Merida buyout
  The big drugmaker’s latest company acquisition this year is centered around a technology designed to degrade proteins that malfunction in autoimmune disorders.
  biopharma_dive · 1mo ago
• AusperBio adds $120M series C to advance hep B oligo therapy through phase 3 and beyond
  AusperBio Therapeutics has raised $120 million in series C funds to advance its oligonucleotide therapy for chronic hepatitis B through phase 3 testing and hopefully on to commercialization.
  fiercebiotech · 1mo ago
• An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapies
  Aurora Therapeutics, the first company that focused on creating bespoke gene editing treatments, has laid off several staff members and stopped its lead program. The company was using CRISPR base e…
  endpoints · 1mo ago
• Capricor’s Duchenne therapy has new life after FDA grants 3-month extension
  The FDA has granted a three-month extension for Capricor Therapeutics’ Duchenne muscular dystrophy hopeful deramiocel in order to review additional data and consider a refined indication. The new t…
  biospace · 1mo ago